226 related articles for article (PubMed ID: 31125338)
1. Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review.
Toksvang LN; Schmidt MS; Arup S; Larsen RH; Frandsen TL; Schmiegelow K; Rank CU
PLoS One; 2019; 14(5):e0212157. PubMed ID: 31125338
[TBL] [Abstract][Full Text] [Related]
2. Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia.
De Bruyne R; Portmann B; Samyn M; Bansal S; Knisely A; Mieli-Vergani G; Dhawan A
J Hepatol; 2006 Feb; 44(2):407-10. PubMed ID: 16226335
[TBL] [Abstract][Full Text] [Related]
3. The Prevalence of Nodular Regenerative Hyperplasia in Inflammatory Bowel Disease Patients Treated with Thioguanine Is Not Associated with Clinically Significant Liver Disease.
van Asseldonk DP; Jharap B; Verheij J; den Hartog G; Westerveld DB; Becx MC; Russel MG; Engels LG; de Jong DJ; Witte BI; Mulder CJ; van Nieuwkerk CM; Bloemena E; de Boer NK; van Bodegraven AA
Inflamm Bowel Dis; 2016 Sep; 22(9):2112-20. PubMed ID: 27482972
[TBL] [Abstract][Full Text] [Related]
4. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine.
Seiderer J; Zech CJ; Reinisch W; Lukas M; Diebold J; Wrba F; Teml A; Chalupna P; Stritesky J; Schoenberg SO; Schima W; Göke B; Ochsenkühn T
J Hepatol; 2005 Aug; 43(2):303-9. PubMed ID: 15964660
[TBL] [Abstract][Full Text] [Related]
5. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
van Asseldonk DP; Seinen ML; de Boer NK; van Bodegraven AA; Mulder CJ
J Crohns Colitis; 2012 Feb; 6(1):95-101. PubMed ID: 22261533
[TBL] [Abstract][Full Text] [Related]
6. 6-Thioguanine-related chronic hepatotoxicity and variceal haemorrhage in children treated for acute lymphoblastic leukaemia--a dual-centre experience.
Ravikumara M; Hill FG; Wilson DC; Gillett PM; Thomas A; Brown R; Darbyshire PJ; McKiernan PJ
J Pediatr Gastroenterol Nutr; 2006 May; 42(5):535-8. PubMed ID: 16707977
[TBL] [Abstract][Full Text] [Related]
7. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?
Gilissen LP; Derijks LJ; Driessen A; Bos LP; Hooymans PM; Stockbrügger RW; Engels LG
Dig Liver Dis; 2007 Feb; 39(2):156-9. PubMed ID: 17188950
[TBL] [Abstract][Full Text] [Related]
8. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party.
de Boer NK; Reinisch W; Teml A; van Bodegraven AA; Schwab M; Lukas M; Ochsenkühn T; Petritsch W; Knoflach P; Almer S; van der Merwe SW; Herrlinger KR; Seiderer J; Vogelsang H; Mulder CJ;
Digestion; 2006; 73(1):25-31. PubMed ID: 16493198
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia: A protocol for systematic review and meta-analysis.
Chen L; Yan HX; Liu XW; Chen WX
Medicine (Baltimore); 2020 May; 99(18):e20082. PubMed ID: 32358392
[TBL] [Abstract][Full Text] [Related]
10. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.
Vora A; Mitchell CD; Lennard L; Eden TO; Kinsey SE; Lilleyman J; Richards SM; ;
Lancet; 2006 Oct; 368(9544):1339-48. PubMed ID: 17046466
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
Erb N; Harms DO; Janka-Schaub G
Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770
[TBL] [Abstract][Full Text] [Related]
12. Critical assessment of thioguanine treatment for inflammatory bowel diseases: Is it time to rehabilitate this treatment?
Movva R; Haywood A; Khan SA; Florin TH; Oancea I
J Dig Dis; 2017 Sep; 18(9):529-536. PubMed ID: 28834232
[TBL] [Abstract][Full Text] [Related]
13. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension.
Ferlitsch A; Teml A; Reinisch W; Ulbrich G; Wrba F; Homoncik M; Gangl A; Peck-Radosavljevic M; Vogelsang H
Am J Gastroenterol; 2007 Nov; 102(11):2495-503. PubMed ID: 17894846
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.
Toksvang LN; Als-Nielsen B; Bacon C; Bertasiute R; Duarte X; Escherich G; Helgadottir EA; Johannsdottir IR; Jónsson ÓG; Kozlowski P; Langenskjöld C; Lepik K; Niinimäki R; Overgaard UM; Punab M; Räty R; Segers H; van der Sluis I; Smith OP; Strullu M; Vaitkevičienė G; Wik HS; Heyman M; Schmiegelow K
BMC Cancer; 2022 May; 22(1):483. PubMed ID: 35501736
[TBL] [Abstract][Full Text] [Related]
15. Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inherited thiopurine methyltransferase deficiency.
McBride KL; Gilchrist GS; Smithson WA; Weinshilboum RM; Szumlanski CL
J Pediatr Hematol Oncol; 2000; 22(5):441-5. PubMed ID: 11037857
[TBL] [Abstract][Full Text] [Related]
16. Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients.
van Asseldonk DP; Simsek M; de Boer NKH; Jharap B; Bloemena E; den Hartog G; Westerveld DB; Becx MC; Russel MG; Lissenberg-Witte BI; van Nieuwkerk CM; Mulder CJJ; Verheij J; van Bodegraven AA
Scand J Gastroenterol; 2019 Jun; 54(6):753-760. PubMed ID: 31203688
[No Abstract] [Full Text] [Related]
17. Quantification of Thiopurine Nucleotides in Erythrocytes and Clinical Application to Pediatric Acute Lymphoblastic Leukemia.
Moon SY; Lim JH; Kim EH; Nam Y; Yu KS; Hong KT; Choi JY; Hong CR; Kim H; Kang HJ; Shin HY; Lee K; Song J; Lee SY; Song SH
Ther Drug Monit; 2019 Feb; 41(1):75-85. PubMed ID: 30507626
[TBL] [Abstract][Full Text] [Related]
18. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease.
Teml A; Schwab M; Hommes DW; Almer S; Lukas M; Feichtenschlager T; Florin T; Seiderer J; Petritsch W; Bokemeyer B; Kreisel W; Herrlinger KR; Knoflach P; Bonaz B; Klugmann T; Herfarth H; Pedarnig N; Reinisch W
Wien Klin Wochenschr; 2007; 119(17-18):519-26. PubMed ID: 17943403
[TBL] [Abstract][Full Text] [Related]
19. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.
Dubinsky MC; Vasiliauskas EA; Singh H; Abreu MT; Papadakis KA; Tran T; Martin P; Vierling JM; Geller SA; Targan SR; Poordad FF
Gastroenterology; 2003 Aug; 125(2):298-303. PubMed ID: 12891528
[TBL] [Abstract][Full Text] [Related]
20. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients.
de Boer NK; Zondervan PE; Gilissen LP; den Hartog G; Westerveld BD; Derijks LJ; Bloemena E; Engels LG; van Bodegraven AA; Mulder CJ
Dig Liver Dis; 2008 Feb; 40(2):108-13. PubMed ID: 18083079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
